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Giuseppina Novoa,c, Salvatore Giambancoa, Marco Guglielmoa,
Luisa Arvigoa, Maria R. Suteraa, Francesco Giambancob, Salvatore Evolaa,
Loredana Vaccarinoc, Manuela Bovac, Domenico Lioc, Pasquale Assennatoa
and Salvatore NovoaBackground Takotsubo cardiomyopathy (TTC) is an
increasingly reported clinical syndrome that mimics acute
myocardial infarction without obstructive coronary artery
disease and is characterized by transient systolic
dysfunction of the apical and/or mid-segments of the
left ventricle. The syndrome mainly occurs in
postmenopausal women with high adrenergic state
conditions. Nowadays, the pathophysiology of TTC is not yet
known and the possibility of a genetic predisposition is
controversial.
Aims The purpose of this study was to assess the genetic
susceptibility to TTC through analysis of the L41Q
polymorphism of the G-protein-coupled receptor kinase 5
(GRK5).
Methods and results In a cohort of 20 patients enrolled in
two tertiary Italian centers with diagnosis of TTC,
accordingly to the commonly accepted Mayo Clinic criteria
and in 22 healthy individuals (control) we have evaluated the
polymorphism in GRK5 gene. The TTC patients had a mean
age of 65W9 years and 19 of 20 were women. The presenceopyright © Italian Federation of Cardiology. Una
1558-2027  2014 Italian Federation of Cardiologyof one or two L41 alleles of GRK5 was significantly more
frequent in TTC group than in the control group (40 vs. 8%,
PU0.0372).
Conclusion In our study, we have found a significant
difference in the frequency of GRK5 polymorphism between
TTC patients and controls, supporting a genetic
predisposition to this cardiac syndrome.J Cardiovasc Med 2014, 15:000–000
Keywords: genotype, G-protein-coupled receptor kinase 5 gene,
polymorphism, Takotsubo cardiomyopathy
aDivision of Cardiology, A.O. Policlinico ‘P. Giaccone’, University of Palermo,
bDivision of Cardiology, ‘G.F. Ingrassia’ Hospital and cDepartment of
Biopathology and Medical and Forensic Biotechnology, University of Palermo,
Palermo, Italy
Correspondence to Salvatore Giambanco, MD, Division of Cardiology, A.O.
Policlinico ‘P. Giaccone’, University of Palermo, Palermo, Italy
E-mail: g.salvo89@hotmail.it
Received 27 December 2013 Revised 29 March 2014
Accepted 31 March 2014Introduction
Takotsubo cardiomyopathy (TTC), also called ‘stress
cardiomyopathy’ or ‘transient left ventricular apical bal-
looning syndrome’, is an infrequent heart syndrome,
accounting for at least 2% of acute coronary syndrome
(ACS) cases.1 It has received considerable interest from
the scientific community around the world, and in recent
years it has been confirmed by the continuous and
significant increase in publications related to this cardio-
myopathy.2–5 TTC is characterized by transient left
ventricular dysfunction, symptoms, and ECG changes
mimicking acute myocardial infarction (AMI), and mod-
est elevation in cardiac troponin, but in the absence of
obstructive coronary disease or angiographic evidence of
acute plaque rupture.6 Although the syndrome has
usually a benign prognosis and a complete recovery
occurs in 2–3 weeks,7 it occasionally can result in acute
complications, including hemodynamic instability, atrial
and ventricular arrhythmias,8 heart failure, and cardio-
genic shock in a minority of patients.9,10 The risk of
inhospital mortality is low (1–3%).11–13 TTC just over20 years ago was first described by Japanese investi-
gators,6 and subsequently was also recognized by Amer-
ican and European populations.14–17 It occurs almost
exclusively in women, especially in postmenopausal
period, and the onset of acute event is often preceded
by emotional and/or physical stress.18 Classically, left
ventriculography shows ‘apical ballooning’ pattern with
hyperkinesia of the basal segments.19 Recently, new
variants have been described with different wall motion
anomalies of the left ventricle such as ‘midventricular
ballooning’ and sparing or hyperkinesia of the basal and
apical segments, or an ‘inverted Takotsubo’ pattern with
akinesia of the basal portions and hyperkinesia of the
apex.20,21 The right ventricular involvement is increas-
ingly recognized and is associated with a worse prog-
nosis.22
To date, the pathophysiology of TTC is still unclear,23
but the fact that in TTC patients, plasma catecholamines
are elevated two to three times higher than in AMI
patients, has led to one of the most convincinguthorized reproduction of this article is prohibited.
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Table 1 The main clinical characteristics of the study population
(nU20)
Age (meanSD) 659
Female (%) 19 (95)
Emotional/physical stressors (%) 17 (85)
Smoker (%) 6 (30)
Hypertension (%) 14 (70)
Diabetes mellitus (%) 3 (15)
Troponin I peak (meanSD) (ng/ml) 5.986.15
Ejection fraction in acute phase (meanSD) (%) 41.67.6
Ejection fraction at discharge (meanSD) (%) 52.37.2
In-hospital events (%) 2 (10)
Pericarditis 2 (10)hypotheses that it is the result of a transient direct toxic
effect of catecholamines on the myocardium.24 Several
studies have provided evidence that high catecholamine
levels could be responsible for an increase in the expres-
sion and enzymatic activity of G-protein-coupled recep-
tor kinases (GRKs). In physiological conditions, the
intracellular signaling, following catecholamine binding
to the receptor, is mediated by bARs, activating myocytes
by coupling to the Ga subunit of the Gs protein complex.
At the same time, catecholamines promote the activation
of GRK that induces phosphorylation of bARs, which
promotes b-arrestin binding, and G-protein uncoupling
to shut-off signaling. This regulation system is called
‘bARs desensitization’.25,26 The upregulation of GRKs
could be somewhat connected to the desensitization and
downregulation of the b-adrenoceptors (bAR) in the
failing heart, suggesting that genetic GRK variants might
modify outcomes in cardiac failure and ischemia.27–29 Of
the seven human GRKs, GRK2 and GRK5 predominate
in myocardium,29 even if GRK2 seems to be the most
relevant isoform at the cardiovascular level.30–33
Recently, several studies evaluating genetic polymor-
phisms potentially involved in the pathogenesis of
TTC have been published; however, the findings have
been contradictory.34 The aim of our study was to further
investigate the genetic susceptibility to TTC through
analysis of the L41Q polymorphism of the G-protein-
coupled receptor kinase 5 (GRK5), one of the protein
kinases most expressed in the heart and stress-induced
acute ventricular dysfunction.
Methods
From May 2007 to April 2013, we have enrolled consecu-
tive patients with TTC from two Italian tertiary hospitals.
TTC was diagnosed according to the diagnostic criteria of
Mayo Clinic,35 which includes the following. First
criterion is transient hypokinesis, akinesis, or dyskinesis
of the left ventricular mid-segments with or without
apical involvement. The regional wall motion abnormal-
ities typically extend beyond a single epicardial coronary
distribution. Second criterion is the absence of obstruc-
tive coronary disease or angiographic evidence of acute
plaque rupture. Third criterion is new ECG abnormal-
ities (either ST-segment elevation and/or T-wave inver-
sion) or modest elevation in cardiac troponin. Finally, the
fourth criterion is the absence of pheochromocytoma
and myocarditis.
Peripheral blood samples in EDTA have been collected
from each patient of the study group and control group
(healthy individuals). DNA has been extracted using the
‘salting out technique’ and the polymorphism rs17098707
for GRK5 was identified using PCR followed by a
Restriction Fragment Length Polymorphism (RFLP)
analysis as previously described. Written informed con-
sent was given by each participant. Statistical analysis of
data was performed using the Statgraphics software.pyright © Italian Federation of Cardiology. UnauContinuous data were reported as mean standard devi-
ation and categorical data were expressed in number and
percentage. The differences between the groups were
analyzed using the x2 test for categorical variables,
whereas the association between multiple variables was
analyzed using the multivariate linear regression model.
A value of P< 0.05 was considered statistically signifi-
cant.
Results
Of the 43 consecutive TTC patients recruited overall, 20
gave consent for genetic analysis. The main clinical
features of the study population are shown in Table 1.
The analysis of polymorphism rs17098707A/T L41Q for
GRK5 was performed in 20 TTC patients and 22 healthy
individuals were used as control group (Table 2). In the
TTC group, the ‘wild-type’ genotype (AA) was found in
12 patients (60%), whereas the ‘variant’ condition was
found in five patients (25%) in the heterozygosity (AT)
and three patients (15%) in homozygosity state (TT). In
the control group, the expression of the AA genotype was
observed in almost all of the analyzed population (92%) as
the presence of polymorphism for GRK5 was detected
only in one patient (4%) in heterozygosity (AT) and in
one patient (4%) in homozygosity state (TT). Both
groups seem to be in ‘Hardy–Weinberg equilibrium’.
The distribution of genotypes between the two popu-
lations appears significantly different (P¼ 0.0372) with an
increased frequency of genotypes positive for the T allele
in TTC patients. The analysis of the significance of the
frequency distribution of genotypes between patients
and control group shows that homozygous genotype
AA has a high probability of being protective of TTC
(odds ratio¼ 0.150; 95% confidence interval¼ 0.027–
0.827) and the difference in distribution between the
two populations is significant (P¼ 0.0296). The AT
(heterozygous) and TT (homozygous) genotypes do
not seem to have a clear predisposing effect for TTC
and the difference in the genotype distribution between
both groups is not significant (Table 3). About the
frequency distribution of the alleles between patients
and controls (Table 4), it has been found that the
T allele, mainly represented in the TTC group
(P¼ 0.0174), seems to be one of the genetic risk factorsthorized reproduction of this article is prohibited.
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Table 2 Frequency of L41Q polymorphism of the GRK5 in
Takotsubo cardiomyopathy patients and controls
Gene (SNP) Group WT (%) Het (%) Poly (%) P value
GRK5 (rs17098707) Control 92.0 4.0 4.0
TTC 60.0 25.0 15.0 0.0372
GRK5, G-protein-coupled receptor kinase 5; Het, heterozygote; Poly, homozygous
for polymorphism; SNP, single nucleotide polymorphism; TTC, Takotsubo cardio-
myopathy; WT, homozygous for the wild-type.
Table 4 Frequency distribution of the alleles between patients and
control group
N8 analyzed chromosomes Group A Allele (%) T Allele (%) P value
44 Control 93.2 6.8
40 TTC 72.5 27.5 0.0174
A allele, adenin; T allele, thymine.for Takotsubo syndrome (Relative Risk RR¼ 4.033; 95%
confidence interval¼ 1.211–13.431).
Discussion
The stimuli promoting the imbalance of the autonomic
system and triggering TTC are multiple, and the real
challenge for cardiologists is not their determination, but
rather to understand why only some individuals develop
stress cardiomyopathy. The identification of a genetic
susceptibility in TTC, favoring a better understanding of
the pathogenesis of this peculiar syndrome, could allow
the development of more appropriate preventive strat-
egies and tailored treatment.
The adrenal-cardiac axis has been increasingly identified
as an important contributory factor to the pathogenesis of
TTC.36,37 The catecholamines, produced by the adrenal
glands, are released in response to sympathetic nervous
system stimulation, and increased cardiac function. How-
ever, when catecholamine levels remain chronically elev-
ated, bARs desensitization occurs by a process which
involves proteins, including GRKs and b-arrestins, both
of which have been associated with cardiac dysfunction.31
In detail, the bARs are phosphorylated by GRKs, trans-
located, and subsequently internalized after binding to
b-arrestins. b-Arrestin 1 prevents the inhibition of cat-
echolamine release from the adrenal glands, enhances
the secretion of aldosterone, and may contribute to the
pathogenesis of TTC. Furthermore, it inhibits the ino-
tropic effects of cardiac b1ARs, resulting in decreased
cardiac function.37 In addition, increased cardiac GRK2
levels have been described in chronic heart failure
and are associated with elevated sympathetic nervous
system activity. As recently proposed by Santulli et al.,31
GRK2 could be predictive of ventricular remodeling
after myocardial infarction and could facilitate the tailor-
ing of appropriate therapy for high-risk patients. Fusco
et al.32 reported that ischemia causes acute cellular
and mitochondrial accumulation of GRK2, and inducesopyright © Italian Federation of Cardiology. Una
Table 3 Analysis of the significance of the frequency distribution of
genotypes between patients and control group
Genotypes OR 95% CI P value
WT 0.150 0.027–0.827 0.0296
Het 7.000 0.739–66.249 0.0866
Poly 3.500 0.334–36.688 0.345
95% CI, 95% confidence interval; Het, heterozygote; OR, odd ratio; Poly, homo-
zygous for polymorphism; WT, homozygous for the wild-type.mitochondria biogenesis after ischemia/reperfusion, indi-
cating a protective effect of GRK2 for mitochondria after
acute stress. On the other hand, it has been reported that
GRK5-mediated bAR desensitization could provide
adaptive, beneficial effects during early ventricular
decompensation, and prior to frank failure.29 Moreover,
GRKs may reflect other pathophysiologic processes.
Indeed, the ability of the amino terminus of GRK5
(GRK5-NT) in reducing myocardial transcription factor
NF-kB activity and left cardiac hypertrophy has been
demonstrated.33 In recent years, several experimental
and clinical studies analyzing polymorphisms potentially
involved in the pathogenesis of TTC have been pub-
lished. However, the data reported by various studies are
rather controversial.34 Given the known higher frequency
of some polymorphism in the African-American than
white population, racial differences may partly justify
this discrepancy.38–40 Specifically, the genetic variants
most extensively investigated have been those affecting
cardiac adrenergic receptor (AR) subtypes (a, b1, and
b2), Gs-protein alpha subunit (GNAS), and GRK5.
Zaroff et al.41 have shown an association between poly-
morphisms of the genes encoding the b1-adrenergic
receptor (ADRB1 Arg389Gly and Ser49Gly), b2 (ADRB2
Gly16Arg, Gln27Glu, and Thr164Ile), and a2c (ADRA2C
del322–325) and cardiac dysfunction attributed to the
release of catecholamines after subarachnoid hemorrhage
(SAH). In particular, the authors conclude that ADRB1
and ADRA2C polymorphisms are associated with an
increased risk of cardiac abnormalities after SAH. These
data support the hypothesis that cardiac dysfunction after
SAH is a form of neurocardiogenic injury. Note that, the
regional dysfunction reversible left ventricular view in
SAH patients is phenotypically similar to that of TTC
patients.
Sharkey et al.42 evaluated, in a cohort of 41 patients with
stress cardiomyopathy, the functional polymorphisms of
adrenergic receptors b1 and a2c already implicated in the
increased activation of the sympathetic nervous system,
but have not found significant differences between TTC
patients and controls.
Handy et al.,43 based on evidence from animal studies,
have also included in their study the evaluation of the
ADRB2, over that of ADRB1 and ADRA2C, assuming
that during stress, when epinephrine is the main circulat-
ing catecholamine, regional differences in epinephrine-
sensitive b2-receptors could explain the myocardialuthorized reproduction of this article is prohibited.
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to their study, the authors conclude that while a molecu-
lar defect in adrenergic signaling remains a plausible
pathogenic mechanism, their data, as well as those of
Sharkey et al., indicate that the TTC is not probably
based on genetic variations in adrenergic receptors.
Spinelli et al.44 have analyzed the genetic polymorphisms
in ADRB1, ADRB2, GNAS, and GRK5 genes in 22 TTC
patients. The prevalence of most of the polymorphisms
was similar between patients and controls, but for L41Q
polymorphism of the GRK5, wherein the glutamine (wild-
type) at position 41 is replaced by leucine, was significantly
more frequent in the TTC group. Specifically, the authors
have hypothesized that this polymorphism could attenuate
the inotropic effect of catecholamines on cardiomyocytes
in confirmation of what has been shown in isolated cells
and in transgenic mice, in which the GRK5 L41 variant
causes a negative inotropic effect under conditions of acute
massive catecholamine release. Moreover, the same poly-
morphism is associated with an increase in bAR desensi-
tization, which may predispose to TTC.
Recently, Figtree et al.,45 in a large Australian cohort of
92 TTC patients, did not find association of genetic
variants in the estrogen receptor-a (ERa), b1AR,
b2AR, and catechol-O-methyl transferase (COMT)
genes, or with the previously implicated GRK5, with
occurrence of TTC. Although their data showed no
evidence for specific genetic variants in GRK5 or bAR
playing a role in susceptibility of an individual to TTC,
the authors believe that this interesting hypothesis
cannot be disputed and further research is needed.
In our study, consistent with the data of Spinelli et al.,44
the percentage of TTC patients who presented the
rs17098707 polymorphism of the GRK5 gene was signifi-
cantly higher than that of controls (P¼ 0.0372). Further-
more, the analysis of data showed that ‘wild-type’
genotype (AA) could be protective against TTC. In
contrast, GRK5 L41 variant, in heterozygous (AT) and
homozygous (TT) genotypes, did not seem to be predis-
posing to TTC, although the T allele could represent one
of the genetic risk factors for this cardiomyopathy
(P¼ 0.0174).
Study limitation
The main limitation of our study is the small sample size;
however, our results do not pretend to clarify the com-
plicated issue concerning the genetic mechanisms that
might modulate the pathogenesis of TTC, rather to
provide the cardiological community with a further obser-
vation.
Conclusion
We found a significant difference in the frequency of
GRK5 polymorphism between TTC patients and con-
trols. These findings reinforce the hypothesis of the rolepyright © Italian Federation of Cardiology. Unauof genetic predisposition in the pathogenesis of TTC.
Thus, a defect in the adrenergic signal remains one of the
most compelling pathogenetic hypotheses in this field.
Further research using larger multicenter studies is
needed to better understand the role of genetics in the
pathophysiology of this syndrome.
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